When selecting mCRPC patients for Pluvicto, which baseline variables do you find most useful or predictive of potential hematologic toxicity?  

e.g., baseline counts, prior taxane exposure, prior EBRT, imaging evidence of marrow-involving disease.

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This question is inspired by the Plenary Session Presentation "Hematologic Toxicity Outcomes of Lu-PSMA-617 in Patients Previously Treated with EBRT for Oligometastatic Disease" by Dr. Daniel B. Rosen